Axalimogene filolisbac

Drug Profile

Axalimogene filolisbac

Alternative Names: ADXS HPV; ADXS-11-001; AXAL; Cervical cancer vaccine - Advaxis; Head and neck cancer vaccine - Advaxis; Listeria cancer vaccine - Advaxis; Listeria monocytogenes vaccine live attenuated - Advaxis; Live attenuated listeria monocytogenes vaccine - Advaxis; Lm Technology™; Lm-Listeriolysin-O-fetal liver kinase-1; Lm-LLO-E7; Lm-LLO-E7 vaccine; Lovaxin-C

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Advaxis
  • Developer Advaxis; Brown University Medical School; Cancer Research UK; Gynecologic Oncology Group; Icahn School of Medicine at Mount Sinai; MedImmune
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer; Anal cancer; Cervical cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cervical cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Anal cancer; Head and neck cancer; Oropharyngeal cancer
  • Discontinued Cervical intraepithelial neoplasia

Most Recent Events

  • 24 Mar 2017 The EMA issues advanced therapy medicinal product certificate for manufacturing quality and non-clinical data for axalimogene filolisbac in Cervical cancer (Metastatic disease)
  • 09 Jan 2017 Advaxis announces intention to submit MAA to EMA for Cervical cancer in H2 2017
  • 09 Jan 2017 Advaxis plans a global registrational phase III trial for Cervical cancer (Metastatic disease, Recurrent)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top